Glutamate and dopamine components in schizophrenia.

Abstract

The treatment of schizophrenia for the last half century has been with dopamine (DA) D(2) receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report found that the glutamate agonist LY404039 was effective in schizophrenia, suggesting a hypoglutamate state for the illness. Although phencyclidine psychosis also supports a hypoglutamate cause, assessing the basic and clinical findings shows that phencyclidine has DA D(2) agonist actions as well. Accurate Dreiding models of phencyclidine and the LY glutamate agonists precisely fit the known tetrahedral model of the D(2) receptor that accommodates all DA agonists. A further view is that metabotropic glutamate agonists also exert D(2) agonism, and their antipsychotic doses (about 100 mg/d) are predicted by their dissociation constants (about 20 nM) for D(2). Hence, the clinical antipsychotic action of a glutamate agonist may depend on its ability to interfere with DA neurotransmission by its DA partial agonism.

• Authors: Philip Seeman
• Journal: Journal of psychiatry & neuroscience : JPN (J Psychiatry Neurosci) Vol. 34 Issue 2 Pg. 143-9 (Mar 2009) ISSN: 1488-2434 [Electronic] Canada
• PMID: 19270765 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Dopamine Agonists
• Excitatory Amino Acid Agonists
• Receptors, Dopamine D2
• Receptors, Glutamate
• Glutamic Acid
• Dopamine

Topics

• Animals
• Disease Models, Animal
• Dopamine (physiology)
• Dopamine Agonists (pharmacology)
• Excitatory Amino Acid Agonists (therapeutic use)
• Glutamic Acid (physiology)
• Humans
• Receptors, Dopamine D2 (agonists)
• Receptors, Glutamate (drug effects)
• Schizophrenia (metabolism, physiopathology)